Can-Fite BioPharma Ltd. (TASE:CFBI) has begun recruiting patients for a Phase II clinical trial of its CF101 treatment for glaucoma, following a Ministry of Health go-ahead. The trial will be conducted at several medical centers in Israel.
The first stage of the Phase II trial will include 40 patients, who will receive either CF101 or a placebo for four months. After analysis of the interim results, the trial will be expanded to other two dosage groups, and will also be expanded to other countries.
Glaucoma is a major reason for blindness affecting 90 million people worldwide. It damages the optic nerve. The company estimates the current global market for glaucoma treatments at $5.5 billion, which will grow to $8.4 billion in 2012.
Can-Fite's share rose 6.7% at the opening on the TASE today to NIS 0.59, giving a market cap of NIS 120 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 23, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010